CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Phase 2
Active, not recruiting
NCT04231851
| Condition | Acute Myelogenous Leukemia Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | University of California, Irvine |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 30 participants |
|---|
| Interventions | Glasdegib, CPX-351 |
|---|
| Start date | Feb 19, 2020 |
|---|
| Completion date | Jun 30, 2024 |
|---|
| Results posted | Mar 6, 2026 |
|---|
Summary
This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.
Percentage of Participants With Event-Free Survival at 6 Months
6 months · percentage of participants
| CPX-351 and Glasdegib | 31 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.